Explore by Goal

Quick Explanation Copied

Xavier Tekpli is a highly productive cancer epigenetics researcher with a strong focus on DNA methylation, tumor microenvironment, and breast cancer. His OpenAlex metrics show 120 works, 2134 citations, and h-index 27, indicating substantial impact, especially in DNA methylation and cancer biology. The most influential works include Nature Communications breast cancer methylation studies (2019; 2017), and several cancer/epigenetics papers with robust OA availability. Limitations include observational designs and variable cohort sizes across studies; functional validation in some contexts remains limited. Inline citations below summarize key sources and their strengths/limits.

Long Explanation

Author Review: Xavier Tekpli

Bottom line: Xavier Tekpli is a prolific investigator in cancer epigenetics, with a pronounced focus on DNA methylation, enhancer regulation, immune contexture, and tumor microenvironment, particularly in breast cancer. His work contributes to understanding how epigenetic states shape tumor behavior and patient outcomes, often leveraging DNA methylation data, enhancer dynamics, and spatial/immune context information.

Key quantitative metrics

OpenAlex top author profile indicates 120 works and 2134 cited-by, with an h-index of 27 for Xavier Tekpli (openalex profile). This suggests sustained, substantial impact across multiple studies and collaborations.

Representative high-impact papers (selected)

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment (Nature Communications, 2019). This study links tumor immune microenvironment stratification with prognosis, highlighting how epigenetic and immune contexts co-associate with outcomes. OA: Gold. Primary authors include Tekpli and colleagues at Oslo University Hospital.
DNA methylation at enhancers identifies distinct breast cancer lineages (Nature Communications, 2017). Elucidates enhancer methylation landscapes distinguishing breast cancer lineages, underscoring epigenetic heterogeneity. OA: Gold.
DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer (International Journal of Cancer, 2011). Highlights promoter methylation of inflammatory cytokines in lung cancer, a relevant link between epigenetics and tumor-immune interactions. OA: Bronze/Green, depending on platform.
DNA methylation at enhancers identifies distinct breast cancer lineages and Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer (Scientific Reports, 2020). These works illustrate integration of methylation/epigenomics with spatial and phenotypic heterogeneity in tumors.

Scientific strengths

Deep focus on DNA methylation, enhancers, and their roles in tumor subtype delineation and prognosis in breast cancer. This includes promoter- and enhancer-level methylation analyses and integration with gene regulation.
Contributions to tumor microenvironment and immune context in breast cancer, linking methylation/epigenetic patterns to immune landscape and prognosis. Nature Communications (2019) provides one of the clearest demonstrations of immune contexture defining subtypes with prognostic relevance.
Cross-disciplinary methods, combining methylation, transcriptomics, and spatial pathology informatics, as seen in Spatial transcriptomics work (Scientific Reports, 2020). This demonstrates methodological breadth and translational relevance.

Caveats and limitations

Many cited works are observational/association-based, limiting causal inferences about how specific methylation changes drive tumor behavior. While multi-omics integration strengthens interpretations, there remains a need for functional validation. For example, the 2019 breast cancer immune microenvironment paper emphasizes associations that require further mechanistic follow-up.
Variations in open-access status across key papers may affect accessibility of full datasets or methods, potentially impacting reproducibility attempts. Some papers are bronze/green OA, while others are gold OA; platform access can vary by institution.
While Tekpli’s group has strong regional collaboration (Oslo University Hospital and partners), some co-authored works appear with multiple institutions, which can introduce heterogeneity in cohorts and protocols; cross-cohort validation would bolster generalizability across diverse populations.

Open Alex metrics and author standing

OpenAlex lists Tekpli as a top author with a robust publication record and an h-index around 27, reflecting sustained influence over more than a decade. This aligns with the observed impact of his breast cancer epigenetics and immune-contexture work.

Visual data summary

Feedback:

Updated: March 18, 2026

Key Insight

Epigenetic states and immune contexture together shape breast cancer prognosis; integrating spatial pathology with methylomics can uncover clinically actionable subtypes.

Keep Exploring

What mechanistic links exist between Tekpli's enhancer methylation findings and specific immune cell recruitment in breast cancer?

What functional assays would most strengthen causal inferences from his observational epigenetic studies?

Analysis Wizard

Summarizes a high-level, non-technical description of a bioinformatics analysis to assess Tekpli's methylation-based subtypes across cohorts.

Hypothesis Graveyard

Non-reproducible enhancer methylation signatures across diverse populations would challenge the generalizability of tissue-specific lineage models.

If spatial transcriptomics signals are mostly driven by sampling bias rather than true heterogeneity, the proposed links to survival may be overstated.

Potential Experiments

Perform CRISPR-based perturbations of candidate enhancer methylation sites in breast cancer cell lines to test causal effects on gene expression and immune-related pathways.

Cross-cohort validation using multi-center datasets with standardized methylation and spatial-profiling protocols to test enhancer-based lineage signatures and prognostic value across diverse populations.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

I am not biased toward any treatment or policy; focus is on scientific evidence and methodological rigor.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.